Background: The production of growth factors from several experimental arterial conduits was determined. Methods: We implanted 105 experimental arterial grafts that were 1 cm long in the abdominal aorta of Lewis rats (average weight, 250 g). Five different types of grafts were analyzed: arterial isografts, vein grafts, arterial allografts, and polytetrafluoroethylene (PTFE) grafts with normal or decreased compliance. Animals were killed humanely 4 weeks after surgery and the production of platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth factor-b, tumor necrosis factor-a, and interleukin-1 was analyzed. Results: Myointimal hyperplasia (MH) was evident in vein grafts, arterial allografts, and PTFE grafts, but not in arterial isografts. Growth factor production was increased for grafts prone to develop MH like vein, PTFE grafts, and arterial allografts. PDGF and bFGF were increased significantly for PTFE and vein grafts, but not for arterial allografts. The importance of bFGF and PGDF was confirmed by the capability of antibody to PDGF and to bFGF to reduce the mitogenic activity of smooth muscle cells, in vivo and in vitro, for PTFE and vein grafts, but not for arterial allografts, in which a predominant role was played by interleukin-1 and tumor necrosis factor-a. Conclusions: Agents able to neutralize this increased production of growth factors, either directly or by competition with their receptors, can prevent MH formation. (J Vasc Surg 2016;64:1444-9.) Clinical Relevance: Arterial grafts release growth factors, which can lead to myointimal hyperplasia formation and atherosclerosis progression in the arterial tree. Both phenomena can cause graft occlusion. Inhibition of growth factor release by arterial grafts can improve their clinical effectiveness.

Growth factors and experimental arterial grafts / Sterpetti, Antonio; Lepidi, Sandro; Borrelli, Valeria; DI MARZO, Luca; Sapienza, Paolo; Cucina, Alessandra; Ventura, Marco. - In: JOURNAL OF VASCULAR SURGERY. - ISSN 0741-5214. - STAMPA. - 64:5(2016), pp. 1444-1449. [10.1016/j.jvs.2015.07.091]

Growth factors and experimental arterial grafts

STERPETTI, ANTONIO
;
BORRELLI, Valeria;DI MARZO, Luca;SAPIENZA, Paolo;CUCINA, Alessandra;
2016

Abstract

Background: The production of growth factors from several experimental arterial conduits was determined. Methods: We implanted 105 experimental arterial grafts that were 1 cm long in the abdominal aorta of Lewis rats (average weight, 250 g). Five different types of grafts were analyzed: arterial isografts, vein grafts, arterial allografts, and polytetrafluoroethylene (PTFE) grafts with normal or decreased compliance. Animals were killed humanely 4 weeks after surgery and the production of platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth factor-b, tumor necrosis factor-a, and interleukin-1 was analyzed. Results: Myointimal hyperplasia (MH) was evident in vein grafts, arterial allografts, and PTFE grafts, but not in arterial isografts. Growth factor production was increased for grafts prone to develop MH like vein, PTFE grafts, and arterial allografts. PDGF and bFGF were increased significantly for PTFE and vein grafts, but not for arterial allografts. The importance of bFGF and PGDF was confirmed by the capability of antibody to PDGF and to bFGF to reduce the mitogenic activity of smooth muscle cells, in vivo and in vitro, for PTFE and vein grafts, but not for arterial allografts, in which a predominant role was played by interleukin-1 and tumor necrosis factor-a. Conclusions: Agents able to neutralize this increased production of growth factors, either directly or by competition with their receptors, can prevent MH formation. (J Vasc Surg 2016;64:1444-9.) Clinical Relevance: Arterial grafts release growth factors, which can lead to myointimal hyperplasia formation and atherosclerosis progression in the arterial tree. Both phenomena can cause graft occlusion. Inhibition of growth factor release by arterial grafts can improve their clinical effectiveness.
2016
Allografts Animals Aorta; Abdominal,metabolism Aorta; Abdominal, pathology Aorta; Abdominal, surgery*; Arteries, metabolism; Arteries, pathology; Arteries, transplantation*; Blood Vessel Prosthesis*; Blood Vessel Prosthesis Implantation, instrumentation*; Cell Proliferation; Cells, Cultured Culture; Media, Conditioned, metabolism; Fibroblast Growth Factor 2, metabolism; Hyperplasia Intercellular Signaling; Peptides and Proteins, metabolism*; Interleukin-1, metabolism; Isografts Models, Animal Muscle, Smooth; Vascular, metabolism Muscle, Smooth; Vascular, pathology Muscle, Smooth; Vascular, transplantation Myocytes; Smooth Muscle/metabolism Myocytes, Smooth Muscle, pathology Myocytes; Smooth Muscle, transplantation; Neointima; Platelet-Derived Growth Factor, metabolism; Polytetrafluoroethylene Prosthesis; Design Rats, Inbred Lew Transforming Growth; Factor beta, metabolism Tumor Necrosis; Factor-alpha, metabolism; Veins, metabolism; Veins, pathology; Veins, transplantation*; Substances
01 Pubblicazione su rivista::01a Articolo in rivista
Growth factors and experimental arterial grafts / Sterpetti, Antonio; Lepidi, Sandro; Borrelli, Valeria; DI MARZO, Luca; Sapienza, Paolo; Cucina, Alessandra; Ventura, Marco. - In: JOURNAL OF VASCULAR SURGERY. - ISSN 0741-5214. - STAMPA. - 64:5(2016), pp. 1444-1449. [10.1016/j.jvs.2015.07.091]
File allegati a questo prodotto
File Dimensione Formato  
Sterpetti_Growth-factors_2016.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 721.06 kB
Formato Adobe PDF
721.06 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/894428
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact